Ravi Viswanathan is 10% Owner at Ra Pharmaceuticals, Inc. (RARX). They have made 1 open-market trade across 1 company since 2016, most recently 2016-10-31.
CIK 0001481512
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RARX | 80,223 | $3.8M |
Shares reported on the most recent Form 4, priced at the 2016-10-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RARX | SELL | 2016-10-31 | 2016-10-31 | $13.00 | $4.4M | -1.4% | -3.2% | +16.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.